4 Health Services Stocks Dragging The Industry Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 80 points (0.5%) at 15,453 as of Tuesday, Feb. 4, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,024 issues advancing vs. 894 declining with 170 unchanged.

The Health Services industry currently sits up 0.2% versus the S&P 500, which is up 0.7%. A company within the industry that fell today was Fresenius Medical Care AG & Co. KGaA ( FMS), up 1.0%. Top gainers within the industry include Agilent Technologies ( A), up 1.4%, St Jude Medical ( STJ), up 0.7% and Thermo Fisher Scientific ( TMO), up 0.7%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. CareFusion ( CFN) is one of the companies pushing the Health Services industry lower today. As of noon trading, CareFusion is down $0.90 (-2.3%) to $38.90 on heavy volume. Thus far, 2.6 million shares of CareFusion exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $38.00-$39.47 after having opened the day at $38.00 as compared to the previous trading day's close of $39.80.

CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, respiratory care, and surveillance and analytics. CareFusion has a market cap of $8.6 billion and is part of the health care sector. The company has a P/E ratio of 23.8, above the S&P 500 P/E ratio of 17.7. Shares are down 0.1% year-to-date as of the close of trading on Monday. Currently there are 5 analysts that rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full CareFusion Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Jim Cramer: The S&P 500 Isn’t as Passive as You Might Think

Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market

3 Stocks Reiterated As A Buy: CFN, UTX, WHR

Insider Trading Alert - CFN, VSR And CAVM Traded By Insiders

Jim Cramer on the Stock Market: Spinoffs Are in Vogue